{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:56:26Z","timestamp":1793390186577,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T00:00:00Z","timestamp":1453420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.dld.2015.12.013","type":"journal-article","created":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T18:50:01Z","timestamp":1452883801000},"page":"552-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Patient-reported outcomes with lanreotide Autogel\/Depot for carcinoid syndrome: An international observational study"],"prefix":"10.1016","volume":"48","author":[{"given":"Philippe","family":"Ruszniewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lombard-Bohas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Cuthbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Perros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-0512","authenticated-orcid":false,"given":"Lubo\u0161","family":"Holubec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Delle Fave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Niccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Maisonobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Atlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn E.","family":"Caplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2015.12.013_bib0170","first-page":"28","article-title":"An update on gastroenteropancreatic neuroendocrine tumors","author":"Cives","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.dld.2015.12.013_bib0175","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1055\/s-0031-1291307","article-title":"Neuroendocrine neoplasms of the gastroenteropancreatic system: pathology and classification","volume":"43","author":"Anlauf","year":"2011","journal-title":"Hormone and Metabolic Research"},{"key":"10.1016\/j.dld.2015.12.013_bib0180","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.3748\/wjg.14.5377","article-title":"Neuroendocrine tumors of the gastro-entero-pancreatic system","volume":"14","author":"Massironi","year":"2008","journal-title":"World Journal of Gastroenterology"},{"issue":"Suppl. 7","key":"10.1016\/j.dld.2015.12.013_bib0185","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mdq290","article-title":"Gastrointestinal neuroendocrine tumors","volume":"21","author":"Oberg","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.dld.2015.12.013_bib0190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","article-title":"Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population","volume":"41","author":"Beaumont","year":"2012","journal-title":"Pancreas"},{"key":"10.1016\/j.dld.2015.12.013_bib0195","doi-asserted-by":"crossref","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","article-title":"Neuroendocrine tumors","volume":"13","author":"Kulke","year":"2015","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"Suppl. 7","key":"10.1016\/j.dld.2015.12.013_bib0200","doi-asserted-by":"crossref","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.dld.2015.12.013_bib0205","doi-asserted-by":"crossref","DOI":"10.1159\/000443167","article-title":"Consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2015.12.013_bib0210","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.seminoncol.2012.11.006","article-title":"Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Toumpanakis","year":"2013","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.dld.2015.12.013_bib0215","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.22272","article-title":"Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study","volume":"107","author":"Bajetta","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2015.12.013_bib0220","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O\u2019Toole","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2015.12.013_bib0225","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2015.12.013_bib0230","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1200\/JCO.1999.17.4.1111","article-title":"Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms","volume":"17","author":"Wymenga","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl. 3","key":"10.1016\/j.dld.2015.12.013_bib0235","article-title":"ELECT: A phase 3 study of efficacy and safety of lanreotide Autogel\/Depot treatment for carcinoid syndrome in patients with neuroendocrine tumors","volume":"32","author":"Vinik","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2015.12.013_bib0240","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2015.12.013_bib0245","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl. 3","key":"10.1016\/j.dld.2015.12.013_bib0250","first-page":"S709","article-title":"177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: results of the phase III NETTER-1 trial","volume":"51","author":"Strosberg","year":"2015","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.dld.2015.12.013_bib0255","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10555-015-9573-1","article-title":"Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors","volume":"34","author":"Jim\u00e9nez-Fonseca","year":"2015","journal-title":"Cancer and Metastasis Reviews"},{"key":"10.1016\/j.dld.2015.12.013_bib0260","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","article-title":"Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"52","author":"Khan","year":"2011","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.dld.2015.12.013_bib0265","series-title":"NANETS 2015 Neuroendocrine Tumor Symposium Abstracts website: abstract C1","article-title":"Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: patient exit interviews","author":"Anthony","year":"2015"},{"key":"10.1016\/j.dld.2015.12.013_bib0270","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.cgh.2011.06.014","article-title":"Patient-reported outcomes for irritable bowel syndrome are associated with patients\u2019 severity ratings of gastrointestinal symptoms and psychological factors","volume":"9","author":"Lackner","year":"2011","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2015.12.013_bib0275","series-title":"Oncology Working Party. Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies 17 June 2014 (EMA\/CHMP\/292464\/2014)","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.dld.2015.12.013_bib0280","series-title":"Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","author":"U.S. Department of Health and Human Services FDA","year":"2009"},{"key":"10.1016\/j.dld.2015.12.013_bib0285","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study","volume":"32","author":"Escudier","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2015.12.013_bib0290","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide","volume":"21","author":"Kulke","year":"2014","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.dld.2015.12.013_bib0295","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1185\/03007995.2014.952715","article-title":"Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model","volume":"30","author":"Shingler","year":"2014","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.dld.2015.12.013_bib0300","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","article-title":"Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)","volume":"34","author":"Khan","year":"2011","journal-title":"Alimentary Pharmacology and Therapy"},{"key":"10.1016\/j.dld.2015.12.013_bib0305","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000421-200008000-00020","article-title":"Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors","volume":"23","author":"Ricci","year":"2000","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2015.12.013_bib0310","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2147\/PPA.S34337","article-title":"Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel\u00ae given by either self\/partner or a health care professional","volume":"6","author":"Johanson","year":"2012","journal-title":"Journal of Patient Preference and Adherence"},{"key":"10.1016\/j.dld.2015.12.013_bib0315","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-5-18","article-title":"Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study","volume":"5","author":"Frojd","year":"2007","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1016\/j.dld.2015.12.013_bib0320","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/02841860152703445","article-title":"Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours","volume":"40","author":"Larsson","year":"2001","journal-title":"Acta Oncologica"},{"key":"10.1016\/j.dld.2015.12.013_bib0325","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2354.2007.00781.x","article-title":"Are importance-satisfaction discrepancies with regard to ratings of specific health-related quality-of-life aspects valid indicators of disease- and treatment-related distress among patients with endocrine gastrointestinal tumours?","volume":"16","author":"Larsson","year":"2007","journal-title":"European Journal of Cancer Care"},{"key":"10.1016\/j.dld.2015.12.013_bib0330","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/gut.39.2.279","article-title":"Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients","volume":"39","author":"Ruszniewski","year":"1996","journal-title":"Gut"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865815302334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865815302334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T01:32:01Z","timestamp":1600047121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865815302334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1590865815302334"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2015.12.013","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes with lanreotide Autogel\/Depot for carcinoid syndrome: An international observational study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2015.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}